Abliva AB (publ) (ABLI.ST)
SEK 0.44
(0.23%)
SEK 0.44
(0.23%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -95.5 Million SEK | -12.41% |
| 2022 | -84.96 Million SEK | 31.2% |
| 2021 | -123.49 Million SEK | -106.23% |
| 2020 | -59.88 Million SEK | 22.1% |
| 2019 | -76.87 Million SEK | -12.43% |
| 2018 | -68.37 Million SEK | -2.47% |
| 2017 | -66.72 Million SEK | 5.0% |
| 2016 | -70.24 Million SEK | 22.06% |
| 2015 | -90.11 Million SEK | -111.8% |
| 2014 | -42.54 Million SEK | -90.54% |
| 2013 | -22.33 Million SEK | -50.14% |
| 2012 | -14.87 Million SEK | -58.46% |
| 2011 | -9.38 Million SEK | -96.62% |
| 2010 | -4.77 Million SEK | -212.31% |
| 2009 | -1.52 Million SEK | 1.87% |
| 2008 | -1.55 Million SEK | -26.93% |
| 2007 | -1.22 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -25.75 Million SEK | -41.62% |
| 2024 Q1 | -18.18 Million SEK | 27.95% |
| 2023 Q2 | -21.35 Million SEK | -33.76% |
| 2023 FY | -95.5 Million SEK | -12.41% |
| 2023 Q1 | -15.96 Million SEK | 8.84% |
| 2023 Q3 | -32.95 Million SEK | -54.29% |
| 2023 Q4 | -25.23 Million SEK | 23.42% |
| 2022 Q2 | -22.79 Million SEK | -1.28% |
| 2022 FY | -84.96 Million SEK | 31.2% |
| 2022 Q4 | -17.51 Million SEK | 29.11% |
| 2022 Q1 | -22.5 Million SEK | 38.96% |
| 2022 Q3 | -24.7 Million SEK | -8.39% |
| 2021 Q1 | -21.45 Million SEK | -64.25% |
| 2021 Q3 | -34.85 Million SEK | -14.97% |
| 2021 Q4 | -36.87 Million SEK | -5.79% |
| 2021 FY | -123.49 Million SEK | -106.23% |
| 2021 Q2 | -30.31 Million SEK | -41.28% |
| 2020 Q3 | -10.07 Million SEK | 50.38% |
| 2020 FY | -59.88 Million SEK | 22.1% |
| 2020 Q4 | -13.06 Million SEK | -29.62% |
| 2020 Q2 | -20.31 Million SEK | -22.83% |
| 2020 Q1 | -16.53 Million SEK | 38.99% |
| 2019 FY | -76.87 Million SEK | -12.43% |
| 2019 Q3 | -15.29 Million SEK | 26.34% |
| 2019 Q1 | -13.82 Million SEK | 6.97% |
| 2019 Q4 | -27.1 Million SEK | -77.2% |
| 2019 Q2 | -20.76 Million SEK | -50.25% |
| 2018 Q3 | -14.98 Million SEK | 41.2% |
| 2018 Q2 | -25.48 Million SEK | -95.23% |
| 2018 Q1 | -13.05 Million SEK | -31.79% |
| 2018 FY | -68.37 Million SEK | -2.47% |
| 2018 Q4 | -14.85 Million SEK | 0.83% |
| 2017 FY | -66.72 Million SEK | 5.0% |
| 2017 Q4 | -9.9 Million SEK | 24.85% |
| 2017 Q3 | -13.17 Million SEK | 40.8% |
| 2017 Q2 | -22.26 Million SEK | -34.18% |
| 2017 Q1 | -16.59 Million SEK | -17.25% |
| 2016 FY | -70.24 Million SEK | 22.06% |
| 2016 Q1 | -10.58 Million SEK | -55.29% |
| 2016 Q4 | -14.15 Million SEK | 58.28% |
| 2016 Q3 | -33.91 Million SEK | -192.78% |
| 2016 Q2 | -11.58 Million SEK | -9.44% |
| 2015 Q3 | -53.66 Million SEK | -243.52% |
| 2015 FY | -90.11 Million SEK | -111.8% |
| 2015 Q4 | -6.81 Million SEK | 87.3% |
| 2015 Q1 | -14.01 Million SEK | 14.09% |
| 2015 Q2 | -15.62 Million SEK | -11.51% |
| 2014 Q2 | -13.22 Million SEK | -38.26% |
| 2014 FY | -42.54 Million SEK | -90.54% |
| 2014 Q1 | -9.56 Million SEK | -12.03% |
| 2014 Q4 | -16.3 Million SEK | -372.56% |
| 2014 Q3 | -3.45 Million SEK | 73.91% |
| 2013 Q4 | -8.53 Million SEK | -33.43% |
| 2013 FY | -22.33 Million SEK | -50.14% |
| 2013 Q3 | -6.39 Million SEK | -123.12% |
| 2013 Q2 | -2.86 Million SEK | 36.63% |
| 2013 Q1 | -4.52 Million SEK | 4.27% |
| 2012 Q2 | -3.84 Million SEK | -46.89% |
| 2012 Q3 | -3.67 Million SEK | 4.37% |
| 2012 Q4 | -4.72 Million SEK | -28.51% |
| 2012 FY | -14.87 Million SEK | -58.46% |
| 2012 Q1 | -2.61 Million SEK | -3.6% |
| 2011 Q2 | -3.05 Million SEK | -113.52% |
| 2011 Q4 | -2.52 Million SEK | -6.49% |
| 2011 FY | -9.38 Million SEK | -96.62% |
| 2011 Q1 | -1.43 Million SEK | -7.05% |
| 2011 Q3 | -2.37 Million SEK | 22.27% |
| 2010 Q3 | -1.45 Million SEK | -27.11% |
| 2010 Q1 | -837.64 Thousand SEK | -103.21% |
| 2010 Q4 | -1.33 Million SEK | 8.18% |
| 2010 FY | -4.77 Million SEK | -212.31% |
| 2010 Q2 | -1.14 Million SEK | -36.67% |
| 2009 Q2 | -426.59 Thousand SEK | -11.97% |
| 2009 Q3 | -308.72 Thousand SEK | 27.63% |
| 2009 Q4 | -412.2 Thousand SEK | -33.52% |
| 2009 FY | -1.52 Million SEK | 1.87% |
| 2009 Q1 | -380.97 Thousand SEK | 0.0% |
| 2008 FY | -1.55 Million SEK | -26.93% |
| 2007 FY | -1.22 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -12.82 Million SEK | -644.535% |
| BioArctic AB (publ) | 229.24 Million SEK | 141.662% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -433.659% |
| CombiGene AB (publ) | -35.66 Million SEK | -167.792% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 37.103% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -482.444% |
| OncoZenge AB (publ) | -15.9 Million SEK | -500.61% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 61.579% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 79.513% |
| Mendus AB (publ) | -101.61 Million SEK | 6.013% |
| LIDDS AB (publ) | -40.2 Million SEK | -137.549% |
| Lipum AB (publ) | -37.17 Million SEK | -156.897% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 884.855% |
| Simris Alg AB (publ) | -37.3 Million SEK | -156.022% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -126.201% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -302.364% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 75.395% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 46.841% |
| Ziccum AB (publ) | -21.41 Million SEK | -346.054% |
| AcouSort AB (publ) | -17.08 Million SEK | -458.892% |
| Active Biotech AB (publ) | -45.8 Million SEK | -108.535% |
| Alzinova AB (publ) | -16.48 Million SEK | -479.545% |
| Amniotics AB (publ) | -30.87 Million SEK | -209.391% |
| Camurus AB (publ) | 431.44 Million SEK | 122.137% |
| Cantargia AB (publ) | -280.02 Million SEK | 65.893% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -352.842% |
| Genovis AB (publ.) | 61.5 Million SEK | 255.299% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 15.72% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -157.638% |
| Intervacc AB (publ) | -102.85 Million SEK | 7.139% |
| Kancera AB (publ) | -64.88 Million SEK | -47.188% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 1873.283% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -687.508% |
| NextCell Pharma AB | -41.95 Million SEK | -127.62% |
| Saniona AB (publ) | -95.81 Million SEK | 0.314% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 69.284% |
| Xintela AB (publ) | -54.08 Million SEK | -76.597% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -21705.708% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -478.037% |
| Corline Biomedical AB | -1.8 Million SEK | -5179.657% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 46.295% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -68.088% |
| Aptahem AB (publ) | -11.11 Million SEK | -759.445% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 22.393% |
| Fluicell AB (publ) | -26.55 Million SEK | -259.678% |
| Biovica International AB (publ) | -124.82 Million SEK | 23.484% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 70.783% |
| 2cureX AB (publ) | -32.51 Million SEK | -193.711% |
| I-Tech AB | 20.2 Million SEK | 572.747% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 88.517% |
| Cyxone AB (publ) | -22.98 Million SEK | -315.455% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -4.494% |
| Biosergen AB | -27.03 Million SEK | -253.253% |
| Nanologica AB (publ) | -75.15 Million SEK | -27.079% |
| SynAct Pharma AB | -215.81 Million SEK | 55.744% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -116.8% |
| BioInvent International AB (publ) | -330.3 Million SEK | 71.085% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 61.66% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -861.822% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 12.608% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -717.854% |